Hypertrophic Cardiomyopathy Secondary to
RAF1
Cysteine-Rich Domain Variants
Circ Genom Precis Med
.
2023 Dec;16(6):e004262.
doi: 10.1161/CIRCGEN.123.004262.
Epub 2023 Oct 31.
Authors
Dominic E Fullenkamp
1
2
,
Ryan M Jorgensen
3
,
Desiree F Leach
3
,
Arjun Sinha
2
,
Isabella M Salamone
1
,
Jamie R Johnston
1
,
Lisa M Dellefave-Castillo
1
2
,
Lubna Choudhury
2
,
Elizabeth M McNally
1
2
,
Lisa D Wilsbacher
2
3
4
Affiliations
1
Center for Genetic Medicine (D.E.F., I.M.S., J.R.J., L.M.D.-C., E.M.M.), Northwestern University, Chicago, IL.
2
Division of Cardiology, Department of Medicine (D.E.F., A.S., L.M.D.-C., L.C., E.M.M., L.D.W.), Northwestern University, Chicago, IL.
3
Feinberg Cardiovascular and Renal Research Institute (R.M.J., D.F.L., L.D.W.), Northwestern University, Chicago, IL.
4
Department of Pharmacology, Feinberg School of Medicine (L.D.W.), Northwestern University, Chicago, IL.
PMID:
37905408
PMCID:
PMC10841507
(available on
2024-12-01
)
DOI:
10.1161/CIRCGEN.123.004262
No abstract available
Keywords:
Noonan syndrome; epidermal growth factor; humans; immunoblotting; phosphorylation.
MeSH terms
Cardiomyopathy, Hypertrophic* / complications
Cardiomyopathy, Hypertrophic* / genetics
Cysteine
Humans
Noonan Syndrome*
Substances
Cysteine
Grants and funding
F31 AR073655/AR/NIAMS NIH HHS/United States
K08 HL163392/HL/NHLBI NIH HHS/United States
R01 HL128075/HL/NHLBI NIH HHS/United States
R01 HL167813/HL/NHLBI NIH HHS/United States